Federal Official Gazette
No updates.
ANS news
No updates.
Open public consultations
- CP 163. Its purpose is to receive contributions on the proposed updates to the List of Health Procedures and Events (Rol), specifically on the preliminary recommendation of non-incorporation for the technologies covered by UAT No. 171 – Inclisiran, UAT No. 175 – Lebrikizumab and UAT No. 176 – Momelotinib. Deadline: Nov 5, 2025 to Nov 24, 2025
Scheduled public hearings
- Public Hearing No. 61, Collection of contributions on the preliminary recommendation of non-incorporation for the following technologies:
(i) UAT 171 – Inclisiran for the treatment of primary hypercholesterolemia or mixed dyslipidemia;
(ii) UAT 175 – Lebrikizumab for the treatment of adult patients with severe atopic dermatitis who have failed, are intolerant to or have a contraindication to cyclosporine; and
(iii) UAT 176 – Momelotinib for the treatment of intermediate- and high-risk myelofibrosis.
Date: November 19, 2025, from 9 a.m. to 1 p.m.
Open public calls for input
There are no open public calls for input.
Open public calls
No updates.
Other news
Half of health plan users fear flaws in the protection of electronic medical record data, study says
Source: futurodasaude.com.br · read the full article
New CFM resolution on medical auditing worries the sector
Source: futurodasaude.com.br · read the full article
Cooperative members give Unimed Cuiabá management 48 hours to call a removal Assembly
Source: odocumento.com.br · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.